Dainippon Sumitomo Awakes To The U.S. Market And Buys Sepracor For $2.6 Billion
Buying the Lunesta marketer gives the Japanese pharma an experienced U.S. regulatory and commercial team ahead of lurasidone launch.
Buying the Lunesta marketer gives the Japanese pharma an experienced U.S. regulatory and commercial team ahead of lurasidone launch.